AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22399760 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually induced gamma-band synchronization in monozygotic twins
Number of subjects: 80
Study 22399760 — intervention group
Group type: COMPARATOR
Intervention: Visually induced gamma-band synchronization in dizygotic twins
Number of subjects: 80
Study 22399760 — intervention group
Group type: COMPARATOR
Intervention: Visually induced gamma-band synchronization in unrelated subjects
Number of subjects: 80
Study 19969615 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart music
Number of subjects: 20
Study 19969615 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 20
Study 18506738 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg ambroxol
Number of subjects: 24
Study 18506738 — intervention group
Group type: COMPARATOR
Intervention: Internal standard: enalaprilat
Number of subjects: 24
Study 18506738 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 24
Study 15937908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg monthly)
Number of subjects: 851
Study 15937908 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1 mg daily)
Number of subjects: 851
Study 15937908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 851
Study 12473476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium Gel (85% ethanol-based) applied under occlusive patch during induction phase (nine applications over three weeks) and one application during challenge phase.
Number of subjects: 53
Study 12473476 — intervention group
Group type: COMPARATOR
Intervention: Sterillium Gel applied twice a day to the forearm for 14 days.
Number of subjects: 53
Study 9838800 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (20 g/day, 5 days/week)
Number of subjects: 0
Study 9838800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7814240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat spread (40% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group B)
Number of subjects: 33
Study 7814240 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat spread (80% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group C)
Number of subjects: 33
Study 7814240 — intervention group
Group type: COMPARATOR
Intervention: Normal spreadable fat (Control Group A)
Number of subjects: 33
Study 2547411 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 2547411 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 322782 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg daily)
Number of subjects: 26
Study 322782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 322782 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 26
Study 30503589 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 186
Study 30503589 — intervention group
Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 186
Study 29737733 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice training (6 hours of intensive vocal therapy one week before surgery)
Number of subjects: 26
Study 29737733 — intervention group
Group type: COMPARATOR
Intervention: Surgical operation only (control group)
Number of subjects: 26
Study 27063895 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-oriented play group
Number of subjects: 186
Study 27063895 — intervention group
Group type: COMPARATOR
Intervention: Play-as-usual group
Number of subjects: 186
Study 24256453 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (GMT)
Number of subjects: 99
Study 24256453 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 99
Study 22642415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with 1% lidocaine and 0.5% bupivacaine without epinephrine
Number of subjects: 30
Study 22642415 — intervention group
Group type: COMPARATOR
Intervention: Injectable saline placebo
Number of subjects: 30
Study 19022441 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal peritoneal closure
Number of subjects: 340
Study 19022441 — intervention group
Group type: COMPARATOR
Intervention: No parietal peritoneal closure (control)
Number of subjects: 340
Study 17845590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg b.i.d. plus additional doses as needed (SMART)
Number of subjects: 3335
Study 17845590 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol 320/9 microg b.i.d. plus as-needed terbutaline
Number of subjects: 3335
Study 17845590 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/250 microg b.i.d. plus as-needed terbutaline
Number of subjects: 3335
Study 15112887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified dialyzers (CLE)
Number of subjects: 32
Study 15112887 — intervention group
Group type: COMPARATOR
Intervention: Cellulosic dialyzers (CLS)
Number of subjects: 32
Study 11948065 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9424683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (Group F) - 300 micrograms‐1200 micrograms/24 h in epidural perfusion
Number of subjects: 40
Study 9424683 — intervention group
Group type: COMPARATOR
Intervention: Methadone (Group M) - 9 mg‐18 mg/24 h in epidural perfusion
Number of subjects: 40
Study 7946161 — intervention group
Group type: EXPERIMENTAL
Intervention: doxazosin, 4 mg daily
Number of subjects: 16
Study 7946161 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 3429068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbenicillin (2 g i.m. every 12 h for 7 days)
Number of subjects: 24
Study 3429068 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (2 g i.m. every 12 h for 7 days)
Number of subjects: 24
Study 3429068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbenicillin
Number of subjects: 24
Study 29164824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT)
Number of subjects: 12
Study 29164824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT) plus Motivational Interviewing (MI)
Number of subjects: 12
Study 29164824 — intervention group
Group type: COMPARATOR
Intervention: Control group (CRT only)
Number of subjects: 12
Study 29037157 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA with ropivacaine (Ep-R)
Number of subjects: 30
Study 29037157 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA with ropivacaine and morphine (Ep-RM)
Number of subjects: 30
Study 29037157 — intervention group
Group type: COMPARATOR
Intervention: IV morphine (IV-M)
Number of subjects: 30
Study 25653155 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐killed Lactobacillus gasseri TMC0356 (1.0×10(9) cfu/day for 4 weeks)
Number of subjects: 28
Study 25653155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23165172 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus botulinum toxin injection (BTX)
Number of subjects: 36
Study 23165172 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 36
Study 21118844 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0 µg kg⁻¹ min⁻¹
Number of subjects: 38
Study 21118844 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 µg kg⁻¹ min⁻¹
Number of subjects: 38
Study 21118844 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 µg kg⁻¹ min⁻¹
Number of subjects: 38
Study 21118844 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil administration
Number of subjects: 38
Study 19000302 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 16
Study 19000302 — intervention group
Group type: COMPARATOR
Intervention: Delayed extubation
Number of subjects: 16
Study 16539549 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive valdecoxib 40 mg at least 30 minutes before initial archwire placement
Number of subjects: 56
Study 16539549 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative valdecoxib 40 mg two hours after initial archwire placement
Number of subjects: 56
Study 16539549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12907532 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed nasal PD solutions (37 degrees C)
Number of subjects: 32
Study 12907532 — intervention group
Group type: COMPARATOR
Intervention: Room temperature nasal PD solutions (22 degrees C)
Number of subjects: 32
Study 10638382 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of 4-androstene-3,17-dione (delta 4)
Number of subjects: 8
Study 10638382 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of 4-androstene-3 beta,17 beta‐diol (delta 4 Diol)
Number of subjects: 8
Study 10638382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 8761562 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily surveillance for illness and fortnightly malaria surveys in Group 1 schoolchildren.
Number of subjects: 249
Study 8761562 — intervention group
Group type: COMPARATOR
Intervention: Two-monthly surveys and weekly home visits in Group 2 subjects.
Number of subjects: 249
Study 8167771 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 degrees position
Number of subjects: 19
Study 8167771 — intervention group
Group type: COMPARATOR
Intervention: 90 degrees position
Number of subjects: 19
Study 3213310 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg fenoterol orally before PGE2-gel application
Number of subjects: 23
Study 3213310 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet before PGE2-gel application
Number of subjects: 23
Study 30222842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (C‐A‐T)
Number of subjects: 24
Study 30222842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactical Mechanical Tourniquet (TMT)
Number of subjects: 24
Study 30222842 — intervention group
Group type: COMPARATOR
Intervention: Comparison of C‐A‐T and TMT
Number of subjects: 24
Study 28116968 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene block (CISB)
Number of subjects: 40
Study 28116968 — intervention group
Group type: COMPARATOR
Intervention: Subacromial infusion of local anesthetic (CSIA)
Number of subjects: 40
Study 24714184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education program using a touch‐screen computer
Number of subjects: 47
Study 24714184 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored education (booklet on asthma)
Number of subjects: 47
Study 24714184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education program
Number of subjects: 47
Study 22525770 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill walking
Number of subjects: 36
Study 22525770 — intervention group
Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 36
Study 22525770 — intervention group
Group type: EXPERIMENTAL
Intervention: N-back task
Number of subjects: 36
Study 19889524 — intervention group
Group type: COMPARATOR
Intervention: Standard healthy diet
Number of subjects: 40
Study 19889524 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + PS (2 g/day)
Number of subjects: 40
Study 17337065 — intervention group
Group type: EXPERIMENTAL
Intervention: I125 brachytherapy
Number of subjects: 532
Study 17337065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 532
Study 17337065 — intervention group
Group type: COMPARATOR
Intervention: Radiation dose of 24 Gy or higher
Number of subjects: 532
Study 16261947 — intervention group
Group type: EXPERIMENTAL
Intervention: oxymetazoline hydrochloride
Number of subjects: 247
Study 11854116 — intervention group
Group type: EXPERIMENTAL
Intervention: rFGF2 at 0, 0.3, 3, or 30 microg/kg
Number of subjects: 337
Study 11854116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 11854116 — intervention group
Group type: EXPERIMENTAL
Intervention: rFGF2 at 30 microg/kg
Number of subjects: 337
Study 9666577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone sodium for 24 hr.
Number of subjects: 50
Study 9666577 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime sodium for 120 hr.
Number of subjects: 50
Study 7992138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dramatic video 'Shadows of the Heart'
Number of subjects: 106
Study 2568210 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-912 2 mg
Number of subjects: 6
Study 2568210 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-912 0.2 mg
Number of subjects: 6
Study 2568210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31374015 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinnaoning capsule (3 pills, 3 times daily for 12 weeks)
Number of subjects: 240
Study 31374015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 pills, 3 times daily for 12 weeks)
Number of subjects: 240
Study 28874142 — intervention group
Group type: EXPERIMENTAL
Intervention: cART with 800 mg efavirenz
Number of subjects: 61
Study 25138109 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (4 × 4 min at 90% of HRmax)
Number of subjects: 20
Study 25138109 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 20
Study 25138109 — intervention group
Group type: COMPARATOR
Intervention: CON (control condition)
Number of subjects: 20
Study 23273831 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop training in evidence-based motivational interviewing (MI) interventions and organizational development activities at intervention sites.
Number of subjects: 20
Study 23273831 — intervention group
Group type: COMPARATOR
Intervention: Care as usual at control sites.
Number of subjects: 20
Study 21649516 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum moxibustion at around 44°C
Number of subjects: 30
Study 21649516 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion device at 39°C
Number of subjects: 30
Study 18637084 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP (Locate, Align, Mark, Puncture)
Number of subjects: 101
Study 18637084 — intervention group
Group type: COMPARATOR
Intervention: LAP (Locate, Align, Puncture)
Number of subjects: 101
Study 18637084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LAMP and LAP
Number of subjects: 101
Study 18637084 — intervention group
Group type: EXPERIMENTAL
Intervention: Most experienced operators
Number of subjects: 101
Study 16436149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 198
Study 16436149 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 198
Study 12958722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole plus Cisapride and Sucralfate
Number of subjects: 248
Study 12958722 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine plus Cisapride and Sucralfate
Number of subjects: 248
Study 10875050 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20‐50 mg/day)
Number of subjects: 861
Study 10875050 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20, 40, or 60 mg/day)
Number of subjects: 861
Study 10875050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study 9172207 — intervention group
Group type: EXPERIMENTAL
Intervention: pain-incompatible imagery
Number of subjects: 39
Study 9172207 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 39
Study 1399203 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg terbinafine twice daily
Number of subjects: 39
Study 1399203 — intervention group
Group type: COMPARATOR
Intervention: 250 mg terbinafine once daily
Number of subjects: 39
Study 3890768 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilipopolysaccharide gammaglobulin given intramuscularly
Number of subjects: 0
Study 3890768 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination controller therapy
Number of subjects: 222
Study 30742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 222
Study 30742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty care
Number of subjects: 222
Study 30742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen sensitization
Number of subjects: 222
Study 30742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Poverty status
Number of subjects: 222
Study 30562322 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming training (SWM)
Number of subjects: 100
Study 30562322 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 100
Study 26419197 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk intake
Number of subjects: 174
Study 26419197 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake from breast milk
Number of subjects: 174
Study 26419197 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake from breast milk
Number of subjects: 174
Study 26419197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty-acid composition
Number of subjects: 174
Study 26419197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient composition of breast milk
Number of subjects: 174
Study 23972329 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkFit program
Number of subjects: 586
Study 22154417 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically guided capsule endoscope (MGCE)
Number of subjects: 61
Study 22154417 — intervention group
Group type: COMPARATOR
Intervention: Gastroscopy (control)
Number of subjects: 61
Study 22154417 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic yield for both MGCE and gastroscopy
Number of subjects: 61
Study 20451788 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination with saliva before TSEP application (153 teeth)
Number of subjects: 46
Study 20451788 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination with saliva after TSEP application (115 teeth)
Number of subjects: 46
Study 20451788 — intervention group
Group type: COMPARATOR
Intervention: Uncontaminated control group (263 teeth)
Number of subjects: 46
Study 18617486 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole
Number of subjects: 1003
Study 18617486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study 18617486 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole (per protocol analysis)
Number of subjects: 1003
Study 18617486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (per protocol analysis)
Number of subjects: 1003
Study 27945464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg TID (escalated to 45 mg TID if no improvement)
Number of subjects: 570
Study 27945464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 11815395 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily for 2 months)
Number of subjects: 126
Study 11815395 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant mixture (containing vitamin C, alpha-lipoic acid, and vitamin E)
Number of subjects: 126
Study 11815395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 10355512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d. + metronidazole (MTR) 250 mg q.i.d.
Number of subjects: 150
Study 10355512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LNS) 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.
Number of subjects: 150
Study 10355512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LNS) 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d.
Number of subjects: 150
Study 10355512 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 150
Study 8952741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (260 mg/day, reduced to 130 mg/day for elderly patients)
Number of subjects: 65
Study 8952741 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (600 mg/day, reduced to 300 mg/day for elderly patients)
Number of subjects: 65
Study 8952741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 65
Study 8952741 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 65
Study 1682159 — intervention group
Group type: EXPERIMENTAL
Intervention: 120mg terfenadine twice daily for 4 weeks
Number of subjects: 10
Study 1682159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6756798 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (halcinonide ointment, 0.1 percent)
Number of subjects: 214
Study 6756798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ointment base)
Number of subjects: 214
Study 31955478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous deep serratus anterior plane block (SAPB)
Number of subjects: 40
Study 31955478 — intervention group
Group type: COMPARATOR
Intervention: Surgically placed continuous thoracic paravertebral block (SPVB)
Number of subjects: 40
Study 30805213 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume exercise group (300 min/week)
Number of subjects: 334
Study 30805213 — intervention group
Group type: COMPARATOR
Intervention: Moderate-volume exercise group (150 min/week)
Number of subjects: 334
Study 28352069 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Butylphthalide and hyperbaric oxygen therapy (HBO)
Number of subjects: 184
Study 28352069 — intervention group
Group type: COMPARATOR
Intervention: Control group (HBO only)
Number of subjects: 184
Study 25920944 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally designed consent pack
Number of subjects: 1950
Study 25920944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone reminders
Number of subjects: 1950
Study 25920944 — intervention group
Group type: COMPARATOR
Intervention: Prior-notification postcard
Number of subjects: 1950
Study 25920944 — intervention group
Group type: COMPARATOR
Intervention: Standard consent pack
Number of subjects: 1950
Study 25920944 — intervention group
Group type: COMPARATOR
Intervention: Postal reminders
Number of subjects: 1950